Isabel A Hujoel1, Joseph A Murray2. 1. Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. 2. Department of Gastroenterology and Hepatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA. murray.joseph@mayo.edu.
Abstract
PURPOSE OF REVIEW: To review the epidemiology, pathophysiology, diagnosis, management, and prognosis of refractory celiac disease, with a specific emphasis on recent literature. RECENT FINDINGS: While the pathophysiology of type I refractory celiac disease remains unclear, there have been advances in the understanding of the pathophysiology of type II refractory celiac disease. This has included recognition of the significant role of interleukin-15 and somatic mutations in JAK1 or STAT3 in the proliferation of aberrant T cells. This in turn has led to potential novel therapies targeting these factors, one of which has reached the clinical trial stage. The morbidity and mortality associated with type II refractory celiac disease remain significant; however, recent advances in the understanding of the pathophysiology of this condition have led to potential therapeutic options that should be investigated.
PURPOSE OF REVIEW: To review the epidemiology, pathophysiology, diagnosis, management, and prognosis of refractory celiac disease, with a specific emphasis on recent literature. RECENT FINDINGS: While the pathophysiology of type I refractory celiac disease remains unclear, there have been advances in the understanding of the pathophysiology of type II refractory celiac disease. This has included recognition of the significant role of interleukin-15 and somatic mutations in JAK1 or STAT3 in the proliferation of aberrant T cells. This in turn has led to potential novel therapies targeting these factors, one of which has reached the clinical trial stage. The morbidity and mortality associated with type II refractory celiac disease remain significant; however, recent advances in the understanding of the pathophysiology of this condition have led to potential therapeutic options that should be investigated.
Authors: A Rubio-Tapia; G Malamut; W H M Verbeek; R L J van Wanrooij; D A Leffler; S I Niveloni; C Arguelles-Grande; B D Lahr; A R Zinsmeister; J A Murray; C P Kelly; J C Bai; P H Green; S Daum; C J J Mulder; C Cellier Journal: Aliment Pharmacol Ther Date: 2016-08-03 Impact factor: 8.171
Authors: W Eigner; K Bashir; C Primas; L Kazemi-Shirazi; F Wrba; M Trauner; H Vogelsang Journal: Aliment Pharmacol Ther Date: 2016-11-25 Impact factor: 8.171
Authors: Barbara Hrdlickova; Chris J Mulder; Georgia Malamut; Bertrand Meresse; Mathieu Platteel; Yoichiro Kamatani; Isis Ricaño-Ponce; Roy L J van Wanrooij; Maria M Zorro; Marc Jan Bonder; Javier Gutierrez-Achury; Christophe Cellier; Alexandra Zhernakova; Petula Nijeboer; Pilar Galan; Sebo Withoff; Mark Lathrop; Gerd Bouma; Ramnik J Xavier; Bana Jabri; Nadine C Bensussan; Cisca Wijmenga; Vinod Kumar Journal: Eur J Gastroenterol Hepatol Date: 2018-08 Impact factor: 2.566
Authors: Saurabh S Mukewar; Ayush Sharma; Alberto Rubio-Tapia; Tsung-Teh Wu; Bana Jabri; Joseph A Murray Journal: Am J Gastroenterol Date: 2017-03-21 Impact factor: 10.864
Authors: Silvia Sedda; Veronica De Simone; Irene Marafini; Gerolamo Bevivino; Roberta Izzo; Omero Alessandro Paoluzi; Alfredo Colantoni; Angela Ortenzi; Paolo Giuffrida; Gino R Corazza; Alessandro Vanoli; Antonio Di Sabatino; Francesco Pallone; Giovanni Monteleone Journal: Immunology Date: 2016-12-12 Impact factor: 7.397
Authors: Wieke H M Verbeek; Marije S Goerres; B Mary E von Blomberg; Joost J Oudejans; Petra E T Scholten; Muhammed Hadithi; Abdul Al-Toma; Marco W J Schreurs; Chris J J Mulder Journal: Clin Immunol Date: 2007-11-26 Impact factor: 3.969
Authors: Yvette H van Beurden; Tom van Gils; Nienke A van Gils; Zain Kassam; Chris J J Mulder; Nieves Aparicio-Pagés Journal: J Gastrointestin Liver Dis Date: 2016-09 Impact factor: 2.008
Authors: María de Lourdes Moreno; Ángel Cebolla; Alba Muñoz-Suano; Carolina Carrillo-Carrion; Isabel Comino; Ángeles Pizarro; Francisco León; Alfonso Rodríguez-Herrera; Carolina Sousa Journal: Gut Date: 2015-11-25 Impact factor: 23.059
Authors: Laura Kivelä; Alberto Caminero; Daniel A Leffler; Maria Ines Pinto-Sanchez; Jason A Tye-Din; Katri Lindfors Journal: Nat Rev Gastroenterol Hepatol Date: 2020-11-20 Impact factor: 46.802